Sala Alessandra, Webber Colin, Halton Jacqueline, Morrison Judy, Beaumont Lesley, Zietak Anna, Barr Ronald
Health Sciences Centre, McMaster University, and McMaster Children's Hospital, Hamilton, Ontario, Canada.
J Clin Densitom. 2006 Jan-Mar;9(1):91-6. doi: 10.1016/j.jocd.2005.10.003. Epub 2006 Mar 27.
Since there is almost no information on whether the concomitant use of diagnostic radioisotopes and radiographic contrast media interferes with dual-energy X-ray absorptiometry (DXA), we investigated these potentially confounding effects. At routine scheduled radiographic follow-up, 40 patients previously treated for malignant lymphomas or solid tumors in Hamilton and Ottawa, Canada were evaluated, 10 in each of the following 4 categories of diagnostic procedure: (1) computed tomography (CT) with intravenous, iodine-based contrast (+/-oral contrast), (2) magnetic resonance imaging (MRI) with gadolinium-based contrast, (3) gallium scan (GS), and (4) technetium bone scan (TBS). Whole body bone mineral content (WB-BMC) and lumbar spine bone mineral density (LS-BMD), total fat mass (TFM), and lean body mass (LBM) were measured by DXA immediately before and after the other radiological studies (on the same day) and then 7 days later. No statistically significant differences were found among WB-BMC, LS-BMD, TFM, and LBM Z-scores immediately before and after MRI, GS, TBS, and 7 days later. The DXA measurements performed immediately before and after CT showed statistically significant differences in WB-BMC (100% vs 124.5%, p<0.001), TFM (100% vs 75.4%, p<0.001), and LBM (100% vs 110%, p<0.001), resulting from the CT contrast agents compromising the precision of the DXA. The DXA results after 7 days were not statistically different from those at baseline. Dual-energy X-ray absorptiometry can be performed in association with other radiological techniques, with the exception of CT conducted with contrast within 1 week. This study provides information that applies not only to patients with cancer but to the general population undergoing diagnostic procedures.
由于几乎没有关于诊断性放射性同位素与放射造影剂联合使用是否会干扰双能X线吸收法(DXA)的信息,我们对这些潜在的混杂效应进行了研究。在加拿大汉密尔顿和渥太华进行的常规影像学随访中,对40例先前接受过恶性淋巴瘤或实体瘤治疗的患者进行了评估,以下4类诊断程序各10例:(1)静脉注射碘造影剂(±口服造影剂)的计算机断层扫描(CT),(2)使用钆造影剂的磁共振成像(MRI),(3)镓扫描(GS),以及(4)锝骨扫描(TBS)。在其他放射学检查之前和之后(同一天)以及7天后,立即通过DXA测量全身骨矿物质含量(WB-BMC)、腰椎骨矿物质密度(LS-BMD)、总脂肪量(TFM)和瘦体重(LBM)。在MRI、GS、TBS之前和之后以及7天后,WB-BMC、LS-BMD、TFM和LBM Z评分之间未发现统计学上的显著差异。CT之前和之后进行的DXA测量显示,WB-BMC(100%对124.5%,p<0.001)、TFM(100%对75.4%,p<0.001)和LBM(100%对110%,p<0.001)存在统计学上的显著差异,这是由于CT造影剂影响了DXA的精度。7天后的DXA结果与基线时无统计学差异。除了在1周内进行的增强CT外,双能X线吸收法可以与其他放射学技术联合进行。这项研究提供的信息不仅适用于癌症患者,也适用于接受诊断程序的普通人群。